Fig. 2.

The application of newly emerged gene-editing technology (CRISPR/Cas9) in the treatment of different solid cancers. The novel gene-editing technology, namely CRISPR/Cas9, effectively targeted the oncogenes, drug-resistance, and tumor-suppressor genes in the treatment of various solid tumors, including breast, lung, liver, prostate, and colorectal cancers from the past couple of years. Based on accumulated data, the CRISPR/Cas9 has been used in knockout/delete the various oncogenes in different cancer treatments as present in a green box. The brown box represents the activation of different tumor suppressor genes. The orange box characterizes the inhibition/suppression of drug-resistance genes by CRISPR/Cas9 in solid tumors [31,35,45,70,74,[115], [116], [117], [118], [119], [120], [121], [122], [123], [124], [125], [126], [127], [128]]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)